- Home
- INZY vs GHG Comparison
INZY vs GHG Comparison
Compare INZY & GHG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INZY
- GHG
- Stock Information
- Founded
- INZY 2015
- GHG 2004
- Country
- INZY United States
- GHG China
- Employees
- INZY N/A
- GHG N/A
- Industry
- INZY Biotechnology: Pharmaceutical Preparations
- GHG Hotels/Resorts
- Sector
- INZY Health Care
- GHG Consumer Discretionary
- Exchange
- INZY Nasdaq
- GHG Nasdaq
- Market Cap
- INZY 321.4M
- GHG 289.4M
- IPO Year
- INZY 2020
- GHG 2018
- Fundamental
- Price
- INZY $3.13
- GHG $2.72
- Analyst Decision
- INZY Strong Buy
- GHG
- Analyst Count
- INZY 7
- GHG 0
- Target Price
- INZY $16.14
- GHG N/A
- AVG Volume (30 Days)
- INZY 313.3K
- GHG 5.0K
- Earning Date
- INZY 11-05-2024
- GHG 11-25-2024
- Dividend Yield
- INZY N/A
- GHG 3.68%
- EPS Growth
- INZY N/A
- GHG 69.37
- EPS
- INZY N/A
- GHG 0.34
- Revenue
- INZY N/A
- GHG $208,477,725.00
- Revenue This Year
- INZY N/A
- GHG N/A
- Revenue Next Year
- INZY N/A
- GHG $8.78
- P/E Ratio
- INZY N/A
- GHG $8.04
- Revenue Growth
- INZY N/A
- GHG 48.19
- 52 Week Low
- INZY $3.08
- GHG $2.31
- 52 Week High
- INZY $7.80
- GHG $4.46
- Technical
- Relative Strength Index (RSI)
- INZY 19.15
- GHG 43.09
- Support Level
- INZY $4.02
- GHG $2.77
- Resistance Level
- INZY $4.74
- GHG $3.00
- Average True Range (ATR)
- INZY 0.27
- GHG 0.09
- MACD
- INZY -0.11
- GHG -0.03
- Stochastic Oscillator
- INZY 2.65
- GHG 20.00
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
About GHG GreenTree Hospitality Group Ltd. American depositary shares each representing one ordinary share
GreenTree Hospitality Group Ltd is a franchised hotel operator in China as franchised and managed hotels represent almost all the hotels in its hotel network. The hotel network of the company comprised approximately 4,059 hotels with nearly 302,497 rooms in China, covering all centrally administrated municipalities and cities throughout all provinces and autonomous regions in China. The company operates its hotels under GreenTree Inns, GreenTree Eastern, Gme, Gya and VX, GreenTree Alliance, Vatica, and others. The company operates solely in China and generates all its revenue from China itself.